» Articles » PMID: 24172067

Ultraviolet A and Riboflavin Therapy As an Adjunct in Corneal Ulcer Refractory to Medical Treatment

Overview
Specialty Ophthalmology
Date 2013 Nov 1
PMID 24172067
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To present a case of corneal ulcer unresponsive to medical treatment, successfully treated with the use of ultraviolet (UV) A and riboflavin collagen crosslinking (CXL) administered twice.

Methods: A 68-year-old diabetic male patient was diagnosed with unilateral severe corneal ulcer. Gram and Giemsa stains and corneal culture results were performed twice, but no specific pathogen could be detected. The clinical presentation suggested fungal infection. The ulcer was unresponsive to extensive medical treatment administered for 10 days. There was an initial response to topical and intrastromal voriconazole administration; however, this was followed by reactivation. Therefore, UVA-riboflavin treatment was performed when the patient was still on medical therapy.

Results: The stromal infiltrate appeared inactive 1 week after UVA-riboflavin CXL treatment. However, reactivation was noticed on the second week, and a second UVA-riboflavin treatment was planned and performed 3 weeks after the first one. The epithelial defect disappeared, and the stromal infiltrate stayed inactive starting from the first week of the second UVA-riboflavin treatment until the last follow-up examination at month 6.

Conclusion: The UVA-riboflavin CXL may be considered in the management of corneal ulcers unresponsive to medical management.

Citing Articles

Repeated sessions of PACK-CXL WA for the treatment of resistant bacterial keratitis: a retrospective study.

Tawfeek M, Ahmed H, Bori A, Rady A BMC Ophthalmol. 2023; 23(1):333.

PMID: 37495952 PMC: 10369738. DOI: 10.1186/s12886-023-03080-3.


Photoactivated Chromophore Corneal Collagen Cross-Linking for Infectious Keratitis (PACK-CXL)-A Comprehensive Review of Diagnostic and Prognostic Factors Involved in Therapeutic Indications and Contraindications.

Barac I, Artamonov A, Balta G, Dinu V, Mehedintu C, Bobirca A J Pers Med. 2022; 12(11).

PMID: 36422083 PMC: 9698237. DOI: 10.3390/jpm12111907.


Corneal cross-linking guards against infectious keratitis: an experimental model.

Marrie A, Abdullatif A, Gamal El Dine S, Yehia R, Saied R, Tolba D Int Ophthalmol. 2022; 43(4):1241-1248.

PMID: 36255611 PMC: 10113293. DOI: 10.1007/s10792-022-02522-z.


Photoactivated Chromophore for Keratitis-Corneal Collagen Cross-Linking (PACK-CXL) Improves Outcomes of Treatment-Resistant Infectious Keratitis.

Gulias-Canizo R, Benatti A, De Wit-Carter G, Hernandez-Quintela E, Sanchez-Huerta V Clin Ophthalmol. 2020; 14:4451-4457.

PMID: 33376299 PMC: 7762451. DOI: 10.2147/OPTH.S284306.


A Review of Corneal Collagen Cross-linking - Current Trends in Practice Applications.

Lim L, Lim E Open Ophthalmol J. 2018; 12:181-213.

PMID: 30123383 PMC: 6062907. DOI: 10.2174/1874364101812010181.